Drug Profile
GSK 589
Alternative Names: GSK589Latest Information Update: 01 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Analgesics; Small molecules
- Mechanism of Action Proto oncogene protein c ret inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Visceral pain
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Visceral-pain in United Kingdom (PO)
- 06 May 2017 Preclinical trials in Visceral pain in United Kingdom (PO)
- 06 May 2017 Pharmacodynamics and pharmacokinetics data from a preclinical study in Visceral pain associated with irritable bowel syndrome presented at the Digestive Disease Week 2017 (DDW-2017)